news center

press releases

5.22.2019

Epic Sciences Appoints New Chief Technology Officer

Epic Sciences announced that it has named Chockalingam “Palani” Palaniappan as its new chief technology officer to help the company advance its Functional Cell Profiling technology to drive global expansion.

Read full release

5.15.2019

Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019

Epic Sciences, Inc. today announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois.

Read full release

5.13.2019

Epic Sciences Launches New Corporate Branding and Website

Epic Sciences announced the launch of a new brand identity, redesigned logo, tagline and website. The new brand changes reflect Epic Sciences’ evolving product portfolio offerings, diverse customer base and expanding global reach.

Read full release

4.23.2019

Epic Sciences Receives CE Mark for Liquid Biopsy Test Collection Kit. Enables Expanded Access to the Company’s Portfolio of Tests

San Diego – April 23, 2019 – Epic Sciences (“Epic”) announced today that it has received a CE mark for its Liquid Biopsy Test Collection Kit, allowing for sale and distribution of the company’s products within the European Economic Area (EEA). This kit is compatible with Epic’s rapidly expanding menu of diagnostic and clinical trial tests, including those for interventional use.

Read full release
all press releases

news

4.5.2019

COMPELO

Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trial

Epic Sciences and its research partners report the use of the company's new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC). The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930).

Read Full Article

3.27.2019

The Pathologist

A Fluid Future - Why are there inconsistencies between different liquid biopsy tests – and how can the field evolve to maximize accuracy and impact?

Advances in disease profiling over recent years have opened new doors in the quest for early diagnosis and personalized treatment, with metastatic prostate cancer being a case in point. As the most widespread malignancy affecting men in the USA – 174,650 new cases and 31,620 deaths are predicted for 2019 – prostate cancer research is crucial. One such breakthrough is the use of liquid biopsy tests to detect circulating tumor DNA (ctDNA) in patients’ blood, offering a minimally invasive method of disease profiling.

Read Full Article

3.25.2019

FierceBiotech

Epic Sciences nets Myriad’s cancer president to serve as its CEO

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO. Sanders takes over for Murali Prahalad—who is stepping down after six years to pursue new opportunities, according to the company—though Prahalad will maintain a seat on Epic’s board of directors.

Read Full Article

3.20.2019

360Dx

Epic Sciences Nabs NY State Approval for AR-V7 Prostate Cancer Test

NEW YORK (360Dx) – Epic Sciences said today that its lab is now licensed by the New York State Department of Health to provide its Oncotype DX AR-V7 Nucleus Detect test for residents with metastatic castration-resistant prostate cancer.

Read Full Article
all News articles

Events

5.31.2019

ASCO 2019

The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019.

More Info

3.29.2019

AACR 2019

The Epic Sciences team attended AACR Annual Meeting - Booth #4455 - in Atlanta, GA from March 29 - April 3, 2019.

More Info

2.14.2019

ASCO GU 2019

The Epic Sciences team attended the ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019.

More Info

12.4.2018

SABCS 2018

The Epic Sciences team attended and exhibited at the San Antonio Breast Cancer Symposium in San Antonio, TX from December 4 - December 8, 2018.

More Info
more events